MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2023.11.060

Медицинская библиотека · Journal of the American Academy of Dermatology · 2023

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.

Blauvelt Andrew, Rich Phoebe, Sofen Howard, Strober Bruce, Merola Joseph F, Lebwohl Mark, Morita Akimichi, Szepietowski Jacek C, Lambert Jo, Hippeli Lauren, Colston Elizabeth, Balagula Eugene, Banerjee Subhashis, Thaçi Diamant

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Scalp involvement in plaque psoriasis is challenging to treat.

OBJECTIVE

To evaluate the efficacy and safety of deucravacitinib (DEUC) in scalp psoriasis.

METHODS

POETYK PSO-1 and PSO-2 were global phase 3, 52-week, double-blinded trials in adults with moderate to severe psoriasis. Patients were randomized 1:2:1 to oral placebo, DEUC 6 mg once daily, or apremilast 30 mg twice daily. This pooled secondary analysis evaluated scalp-specific Physician Global Assessment score of 0 or 1 (0/1), ≥90% improvement from baseline in Psoriasis Scalp Severity Index, and change from baseline in Psoriasis Scalp Severity Index. Adverse events were evaluated through week 16.

RESULTS

Overall, 1084 patients with moderate to severe scalp psoriasis at baseline were included. At week 16, response rates were greater with DEUC versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 (64.0% vs 17.3% vs 37.7%; P < .0001), ≥90% improvement from baseline in Psoriasis Scalp Severity Index (50.6% vs 10.5% vs 26.1%; P < .0001), and change from baseline in Psoriasis Scalp Severity Index. Responses were maintained through 52 weeks with continuous DEUC. Safety was consistent with the entire study population.

LIMITATIONS: Lack of data in milder scalp psoriasis.

CONCLUSION

DEUC was significantly more efficacious than placebo or apremilast in improving moderate to severe scalp psoriasis and was well tolerated.

Для цитирования: Blauvelt Andrew, Rich Phoebe, Sofen Howard, Strober Bruce, Merola Joseph F, Lebwohl Mark, Morita Akimichi, Szepietowski Jacek C, Lambert Jo, Hippeli Lauren, Colston Elizabeth, Balagula Eugene, Banerjee Subhashis, Thaçi Diamant. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.. Journal of the American Academy of Dermatology. 2023. DOI: 10.1016/j.jaad.2023.11.060.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.